SEC Company Response from Traws Pharma, Inc. (TRAW) (CIK 0001130598) (TRAW) — Feb 6, 2018
Traws Pharma, Inc. (TRAW) (CIK 0001130598)
Date: Feb. 6, 2018 · CIK: 0001130598 · Accession: 0001104659-18-006948
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-222374
Letter
Onconova Therapeutics, Inc.
375 Pheasant Run
Newtown, PA 18954
February 6, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention:
Christine Westbrook
Erin Jaskot
Re:
Onconova Therapeutics, Inc.
Registration Statement on Form S-1 (File No. 333-222374)
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Onconova Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended (the “Registration Statement”), so that the Registration Statement may become effective at 5:15 p.m. (Eastern Time) on February 7, 2018, or as soon as practicable thereafter.
Once the Registration Statement has been declared effective, please orally confirm that event with Joanne R. Soslow of Morgan, Lewis & Bockius LLP at (215) 963-5262.
Under separate cover, you will receive today a letter from the underwriter of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement.
ONCONOVA THERAPEUTICS, INC.
By:
/s/ MARK GUERIN
Name:
Mark Guerin
Title:
Chief Financial Officer
Show Raw Text
CORRESP 1 filename1.htm Onconova Therapeutics, Inc. 375 Pheasant Run Newtown, PA 18954 February 6, 2018 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Christine Westbrook Erin Jaskot Re: Onconova Therapeutics, Inc. Registration Statement on Form S-1 (File No. 333-222374) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Onconova Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement, as amended (the “Registration Statement”), so that the Registration Statement may become effective at 5:15 p.m. (Eastern Time) on February 7, 2018, or as soon as practicable thereafter. Once the Registration Statement has been declared effective, please orally confirm that event with Joanne R. Soslow of Morgan, Lewis & Bockius LLP at (215) 963-5262. Under separate cover, you will receive today a letter from the underwriter of the proposed offering joining in the Company’s request for acceleration of the effectiveness of the Registration Statement. ONCONOVA THERAPEUTICS, INC. By: /s/ MARK GUERIN Name: Mark Guerin Title: Chief Financial Officer